The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is invol…

Non-Diabetic

~Estimated

~$500 – $7,500

Actual pay is set by the research site.

The University of Texas Health Science Center at San AntonioNCT07212868

Phase 2

The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD

Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney dise…

Non-diabetic Chronic Kidney Disease

~Estimated

~$75 – $1,800

Actual pay is set by the research site.

VA Office of Research and DevelopmentNCT07060417